10 results about "Ribonucleoside" patented technology

This disclosure relates to 1H-pyrazolo[3,4-d]pyrimidine ribonucleoside compounds of Formula (I) and pharmaceutically acceptable salts thereof, which activate LACTB and are useful for treating diseases or disorders, such as cancer.

The invention discloses a method for rapidly detecting MTHFR (Methylene Tetrahydrofolate Reductase) gene polymorphism based on a complementary probe technology, which comprises the following steps: S1, acquiring a sample: extracting genome DNA (Deoxyribose Nucleic Acid) from a sample to be detected as an amplification template; s2, preparing a reaction system: adding the genome DNA, the upstream primer, the downstream primer, the C probe, the T probe, uracil-N-glycosylase, DNA polymerase, deoxyribonucleoside triphosphate and deoxyuridine triphosphate of the sample to be detected into the reaction system; s3, carrying out PCR (Polymerase Chain Reaction) amplification reaction under the conditions that the temperature is 90-98 DEG C, and the time is 5-20 minutes; performing denaturation at the temperature of 90-98 DEG C for 10-50 seconds; the temperature is 55-69 DEG C, and annealing is conducted for 60-120 s; the temperature is 68-72 DEG C, and extension is carried out for 15-300 s; carrying out 35 to 40 cycles; and S, genotype judgment. A test result is the same as a first-generation sequencing test result, which shows that the detection method of the scheme has relatively high accuracy. Meanwhile, compared with a sequencing method, the method has the advantages that a series of complex follow-up treatment does not need to be carried out on a PCR product, PCR amplification and detection are synchronously carried out, the detection time is greatly shortened, and the detection cost is reduced.

The invention provides a kit for DNA ligation reaction as well as a use method and application thereof. The kit comprises a first component and a second component, wherein the first component comprises a positively charged substance and a first buffer solution; the positively charged substance is selected from at least one of positively charged polypeptide, positively charged protein, positively charged synthetic macromolecule and positively charged glucan; the second component comprises a negatively charged substance and a second buffer solution; the negatively charged substance is selected from at least one of adenosine triphosphate, deoxyribonucleoside triphosphate, oligonucleotide and negatively charged polypeptide. The first component and the second component are arranged in the kit, when the first component and the second component are prepared into a reaction system, a condensate emulsion of hundreds of nanometers to several micrometers can be formed in situ, the condensate emulsion can spontaneously enrich all the components required by the reaction, and an emulsion matrix phase is a gel-like environment; and the ligation reaction efficiency and accuracy can be remarkably improved through the crowding effect between macromolecules.

This application relates to the field of metabolic engineering and genetic engineering technology for production, specifically providing a uracil-producing strain, its construction method, and its application. This strain is... E. coli Knockout of the uridine kinase gene in the W3110 genome udk Simultaneously integrates the T7 RNA polymerase gene; weakens the uridine kinase gene. pyrH Overexpression of carbamoyl phosphate synthase gene carAB ribose-phosphokinase gene prsA pyrimidine-5'-nucleotide nuclease gene ppnN UMP phosphohydrolase gene umpH and umpG Ribonucleotide hydrolase 1 gene rihA and glutamine synthase gene glnA Heterogeneous introduction of wild-type Bacillus subtilis B. subtilis 168 orotate nucleoside monophosphate decarboxylase gene pyrF and orotic acid ribosyltransferase gene pyrE To achieve safe, efficient, and low-cost production of uracil.

RNA molecules comprising selenoribonucleosides are disclosed. In some embodiments, the RNA molecule is an mRNA molecule that encodes a polypeptide. In some embodiments, the nucleoside is situated in a coding region, polyA tail, 5' UTR, or 3' UTR. Also provided are methods of making and using the RNA molecules described herein.

The present application provides a method for the in vitro transcription of a DNA template to RNA, the method comprising providing a mixture comprising a buffer substance, ribonucleoside triphosphate (NTP), one or more magnesium salts at a concentration of about 2 mM to about 60 mM, the DNA template, a recombinant RNA polymerase, and a cap analog comprising a structure of Formula (I), (II), or (III), the mixture comprising a buffer substance, a ribonucleoside triphosphate (NTP), one or more magnesium salts at a concentration of about 2 mM to about 60 mM, the DNA template, a recombinant RNA polymerase, and a cap analog comprising a structure of Formula (I), (II), or (III), and incubating the reaction mixture at about 15 DEG C to about 35 DEG C, optionally about 18 DEG C to about 31 DEG C, for about 1 hour to about 12 hours, thereby producing the RNA.

The present application provides a method for in vitro transcription of a DNA template into RNA, the method comprising providing a mixture comprising a buffer, ribonucleoside triphosphates (NTPs), one or more magnesium salts at a concentration of about 2 mM to about 60 mM, the DNA template, a recombinant RNA polymerase, and a cap analog comprising a structure having formula (I), (II), or (III); and incubating the reaction mixture at about 15° C. to about 35° C., optionally about 18° C. to about 31° C., for about 1 hour to about 12 hours, thereby producing the RNA.

The disclosure relates to in vivo and ex vivo uses of dihydronicotinamide riboside (NRH), dihydronicotinic acid riboside (NARH) and reduced derivatives thereof to treat immune-related disorders (e.g., systemic inflammatory response syndrome and sepsis), kidney disorders (e.g., acute kidney injury and hepatorenal syndrome [HRS]), liver disorders (e.g., acute liver failure and HRS), hemolytic disorders (e.g., hemolysis and hemolytic anemia), and disorders and conditions associated with oxidative stress, damage or injury (e.g., methemoglobinemia and anemia). NRH, NARH and reduced derivatives thereof can be used in vivo or ex vivo alone or in combination with one or more additional therapeutic agents, such as an anti-inflammatory agent or / and an antioxidant.

The invention discloses a preparation method of 3 '-propenyloxy furan ribonucleoside. The preparation method comprises the following steps: (1) protecting ribonucleoside by using tert-butyldimethylsilyl chloride; (2) carrying out complexing on the ribofuranoside protected by tert-butyldimethylsilyl chloride by using dioctyl tin oxide, so as to obtain a TBS-ribofuranoside-tin complex; (3) adding allyl methyl carbonate and tetrakis (triphenylphosphine) palladium into the TBS-ribonucleoside-tin complex for coupling, so as to obtain a coupling compound; 4, tetrabutylammonium fluoride is added into the coupling compound, a TBS protecting group is removed through a reaction, separation and purification are conducted, and the 3 '-propenyloxy ribofuranoside is obtained.According to the method, the 3'-propenyloxy ribofuranoside can be obtained only through one-time separation by adopting a three-step one-pot method, and industrial mass production is facilitated.